New & Notable
Roche, Zealand tout the tolerability of their amylin obesity drug
The Roche–Zealand amylin obesity drug, petrelintide, delivered up to 10.7% weight loss in a phase 2 obesity trial with a "placebo-like tolerability" profile, the companies say.
Lilly rolls out Employer Connect to close obesity coverage gaps
Eli Lilly debuts Employer Connect, a direct-to-employer platform that helps companies make its GLP-1 obesity drug, Zepbound, more affordable and accessible for employees.
FDA continues crackdown on DTC advertising for compounded GLP-1s
Continuing its crackdown on direct-to-consumer advertising, the FDA has sent 30 more warning letters to companies making deceptive claims about their compounded GLP-1 products.
How PBM reforms could push drugmakers into the pricing spotlight
The Consolidated Appropriations Act’s landmark PBM overhaul removes financial incentives tied to pharma list prices, potentially leaving drugmakers to defend their own practices.
— PharmaVoiceHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
U.S. drug pricing pressures rise amid policy shifts, P&R delays
U.S. policy shifts, trade tensions and delays in pricing and reimbursement processes are the top challenges facing the pharmaceutical industry this year, a GlobalData survey finds.
-
Merck, Mayo Clinic launch AI-driven drug discovery partnership
Merck and Mayo Clinic team up on AI-powered drug discovery, combining Merck's AI and ML tools with Mayo's Platform architecture and clinical datasets to drive early development decisions.
-
Lilly's Zepbound–Taltz combo wins again in obesity, psoriasis study
Eli Lilly’s late-stage psoriasis study shows promising results for combining its obesity drug Zepbound with Taltz, potentially setting the stage for expanded approval.
-
Viking Therapeutics pushes GLP-1/GIP obesity pill to phase 3
Viking Therapeutics is progressing the oral version of its leading drug candidate, VK2736, into phase 3 testing this year, following a mid-stage win.
-
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials
AstraZeneca is moving its GLP-1 pill, elecoglipron, into phase 3 development after revealing positive results from two mid-stage studies, with final readouts slated for June.
-
Nearly half of TrumpRx drugs have generic options available
Of the 43 drugs listed on TrumpRx, 20 have generic versions available in the United States. And most others can be purchased through previously existing discount programs.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.